Instrukcja obsługi Zoetis Apoquel

Zoetis Niesklasyfikowane Apoquel

Przeczytaj poniżej 📖 instrukcję obsługi w języku polskim dla Zoetis Apoquel (2 stron) w kategorii Niesklasyfikowane. Ta instrukcja była pomocna dla 4 osób i została oceniona przez 2 użytkowników na średnio 4.5 gwiazdek

Pobierz PDF
Strona 1/2
Immunomodulator
For oral use in dogs only
Caution: Federal (USA) Law restricts this drug to use by or on the order of a licensed
veterinarian.
Description: APOQUEL (oclacitinib maleate) is a synthetic Janus Kinase (JAK) inhibitor. The
chemical composition of APOQUEL is N-methyl[trans-4-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-
ylamino) cyclohexyl]methanesulfonamide (2Z)-2-butenedioate.
The chemical structure of oclacitinib maleate is:
Indications: Control of pruritus associated with allergic dermatitis and control of atopic
dermatitis in dogs at least 12 months of age.
Dosage and Administration: The dose of APOQUEL (oclacitinib maleate) tablets is 0.18 to
0.27 mg oclacitinib/lb (0.4 to 0.6 mg oclacitinib/kg) body weight, administered orally, twice
daily for up to 14 days, and then administered once daily for maintenance therapy. APOQUEL
may be administered with or without food.
Dosing Chart
Weight Range
(in lb)
Weight Range
(in Kg)
Number of Tablets to be
Administered
Low High Low High 3.6 mg
Tablets
5.4 mg
Tablets
16 mg
Tablets
6.6 9.9 3.0 4.4 - - 0.5
10.0 14.9 4.5 5.9 - - 0.5
15.0 19.9 6.0 8.9 - -1
20.0 29.9 9.0 13.4 - -1
30.0 44.9 13.5 19.9 - - 0.5
45.0 59.9 20.0 26.9 - -2
60.0 89.9 27.0 39.9 - - 1
90.0 129.9 40.0 54.9 - - 1.5
130.0 175.9 55.0 80.0 - - 2
Warnings:
APOQUEL is not for use in dogs less than 12 months of age (see ).Animal Safety
APOQUEL modulates the immune system.
APOQUEL is not for use in dogs with serious infections.
APOQUEL may increase susceptibility to infection, including demodicosis, and exacerbation of
neoplastic conditions (see Precautions, Adverse Reactions, Post-Approval Experience and
Animal Safety).
New neoplastic conditions (benign and malignant) were observed in dogs treated with
APOQUEL during clinical studies and have been reported in the post-approval period
(see ).Adverse Reactions and Post-Approval Experience
Consider the risks and benefits of treatment prior to initiating APOQUEL in dogs with a history
of recurrent serious infections or recurrent demodicosis or neoplasia (see Adverse Reactions,
Post-Approval Experience Animal Safety, and ).
Keep APOQUEL in a secure location out of reach of dogs, cats, and other animals to prevent
accidental ingestion or overdose.
Human Warnings:
This product is not for human use. Keep this and all drugs out of reach of children. For use
in dogs only. Wash hands immediately after handling the tablets. In case of accidental eye
contact, flush immediately with water or saline for at least 15 minutes and then seek medical
attention. In case of accidental ingestion, seek medical attention immediately.
Precautions:
Dogs receiving APOQUEL should be monitored for the development of infections, including
demodicosis, and neoplasia.
The use of APOQUEL has not been evaluated in combination with glucocorticoids,
cyclosporine, or other systemic immunosuppressive agents.
APOQUEL is not for use in breeding dogs, or pregnant or lactating bitches.
Adverse Reactions:
Control of Atopic Dermatitis
In a masked field study to assess the effectiveness and safety of oclacitinib for the control
of atopic dermatitis in dogs, 152 dogs treated with APOQUEL and 147 dogs treated with
placebo (vehicle control) were evaluated for safety. The majority of dogs in the placebo group
withdrew from the 112-day study by Day 16. Adverse reactions reported (and percent of
dogs affected) during Days 0-16 included diarrhea (4.6% APOQUEL, 3.4% placebo), vomiting
(3.9% APOQUEL, 4.1% placebo), anorexia (2.6% APOQUEL, 0% placebo), new cutaneous or
subcutaneous lump (2.6% APOQUEL, 2.7% placebo), and lethargy (2.0% APOQUEL, 1.4%
placebo). In most cases, diarrhea, vomiting, anorexia, and lethargy spontaneously resolved
with continued dosing. Dogs on APOQUEL had decreased leukocytes (neutrophil, eosinophil,
and monocyte counts) and serum globulin, and increased cholesterol and lipase compared
to the placebo group but group means remained within the normal range. Mean lymphocyte
counts were transiently increased at Day 14 in the APOQUEL group.
Dogs that withdrew from the masked field study could enter an unmasked study where all
dogs received APOQUEL. Between the masked and unmasked study, 283 dogs received at
least one dose of APOQUEL. Of these 283 dogs, two dogs were withdrawn from study due
to suspected treatment-related adverse reactions: one dog that had an intense flare-up of
dermatitis and severe secondary pyoderma after 19 days of APOQUEL administration, and one
dog that developed generalized demodicosis after 28 days of APOQUEL administration. Two
other dogs on APOQUEL were withdrawn from study due to suspected or confirmed malignant
neoplasia and subsequently euthanized, including one dog that developed signs associated
with a heart base mass after 21 days of APOQUEL administration, and one dog that developed
a Grade III mast cell tumor after 60 days of APOQUEL administration.
One of the 147 dogs in the placebo group developed a Grade I mast cell tumor and was
withdrawn from the masked study. Additional dogs receiving APOQUEL were hospitalized
for diagnosis and treatment of pneumonia (one dog), transient bloody vomiting and stool
(one dog), and cystitis with urolithiasis (one dog).
In the 283 dogs that received APOQUEL, the following additional clinical signs were reported
after beginning APOQUEL (percentage of dogs with at least one report of the clinical sign as
a non-pre-existing finding): pyoderma (12.0%), non-specified dermal lumps (12.0%), otitis
(9.9%), vomiting (9.2%), diarrhea (6.0%), histiocytoma (3.9%), cystitis (3.5%), anorexia (3.2%),
lethargy (2.8%), yeast skin infections (2.5%), pododermatitis (2.5%), lipoma (2.1%), polydipsia
(1.4%), lymphadenopathy (1.1%), nausea (1.1%), increased appetite (1.1%), aggression
(1.1%), and weight loss (0.7).
Control of Pruritus Associated with Allergic Dermatitis
In a masked field study to assess the effectiveness and safety of oclacitinib for the control of
pruritus associated with allergic dermatitis in dogs, 216 dogs treated with APOQUEL and
220 dogs treated with placebo (vehicle control) were evaluated for safety. During the 30-day
study, there were no fatalities and no adverse reactions requiring hospital care. Adverse
reactions reported (and percent of dogs affected) during Days 0-7 included diarrhea
(2.3% APOQUEL, 0.9% placebo), vomiting (2.3% APOQUEL, 1.8% placebo), lethargy
(1.8% APOQUEL, 1.4% placebo), anorexia (1.4% APOQUEL, 0% placebo), and polydipsia
(1.4% APOQUEL, 0% placebo). In most of these cases, signs spontaneously resolved with
continued dosing. Five APOQUEL group dogs were withdrawn from study because of:
darkening areas of skin and fur (1 dog); diarrhea (1 dog); fever, lethargy and cystitis (1 dog);
an inflamed footpad and vomiting (1 dog); and diarrhea, vomiting, and lethargy (1 dog). Dogs
in the APOQUEL group had a slight decrease in mean white blood cell counts (neutrophil,
eosinophil, and monocyte counts) that remained within the normal reference range. Mean
lymphocyte count for dogs in the APOQUEL group increased at Day 7, but returned to
pretreatment levels by study end without a break in APOQUEL administration. Serum
cholesterol increased in 25% of APOQUEL group dogs, but mean cholesterol remained
within the reference range.
Continuation Field Study
After completing APOQUEL field studies, 239 dogs enrolled in an unmasked (no placebo
control), continuation therapy study receiving APOQUEL for an unrestricted period of time.
Mean time on this study was 372 days (range 1 to 610 days). Of these 239 dogs, one
dog developed demodicosis following 273 days of APOQUEL administration. One dog
developed dermal pigmented viral plaques following 266 days of APOQUEL administration.
One dog developed a moderately severe bronchopneumonia after 272 days of APOQUEL
administration; this infection resolved with antimicrobial treatment and temporary
discontinuation of APOQUEL. One dog was euthanized after developing abdominal ascites
and pleural effusion of unknown etiology after 450 days of APOQUEL administration. Six dogs
were euthanized because of suspected malignant neoplasms: including thoracic metastatic,
abdominal metastatic, splenic, frontal sinus, and intracranial neoplasms, and transitional cell
carcinoma after 17, 120, 175, 49, 141, and 286 days of APOQUEL administration, respectively.
Two dogs each developed a Grade II mast cell tumor after 52 and 91 days of APOQUEL
administration, respectively. One dog developed low grade B-cell lymphoma after 392 days
of APOQUEL administration. Two dogs each developed an apocrine gland adenocarcinoma
(one dermal, one anal sac) after approximately 210 and 320 days of APOQUEL administration,
respectively. One dog developed a low grade oral spindle cell sarcoma after 320 days of
APOQUEL administration.
Post-Approval Experience (2020):
The following adverse events are based on post-approval adverse drug experience reporting
for APOQUEL. Not all adverse events are reported to FDA/CVM. It is not always possible to
reliably estimate the adverse event frequency or establish a causal relationship to product
exposure using these data.
The following adverse events reported in dogs are listed in decreasing order of reporting
frequency.
Vomiting, lethargy, anorexia, diarrhea, elevated liver enzymes, dermatitis (i.e. crusts,
pododermatitis, pyoderma), seizures, polydipsia, and demodicosis.
Benign, malignant, and unclassified neoplasms, dermal masses (including papillomas and
histiocytomas), lymphoma and other cancers have been reported.
Death (including euthanasia) has been reported.
Contact Information:
To report suspected adverse events, for technical assistance or to obtain a copy of the
Safety Data Sheet, contact Zoetis Inc. at 1-888-963-8471 or www.zoetis.com.
For additional information about adverse drug experience reporting for animal drugs, contact
FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.
Clinical Pharmacology:
Mechanism of Action
Oclacitinib inhibits the function of a variety of pruritogenic cytokines and pro-inflammatory
cytokines, as well as cytokines involved in allergy that are dependent on JAK1 or JAK3 enzyme
activity. It has little effect on cytokines involved in hematopoiesis that are dependent on JAK2.
Oclacitinib is not a corticosteroid or an antihistamine.
Pharmacokinetics
In dogs, oclacitinib maleate is rapidly and well absorbed following oral administration,
with mean time to peak plasma concentrations (T
max
) of less than 1 hour. Following oral
administration of 0.4-0.6 mg oclacitinib/kg to 24 dogs, the mean (90% confidence limits
[CL]) maximum concentration (C
max
) was 324 (281, 372) ng/mL and the mean area under the
plasma concentration-time curve from 0 and extrapolated to infinity (AUC
0-inf
) was 1890 (1690,
2110) ng·hr/mL. The prandial state of dogs does not significantly affect the rate or extent of
absorption. The absolute bioavailability of oclacitinib maleate was 89%.
Oclacitinib has low protein binding with 66.3-69.7% bound in fortified canine plasma at
nominal concentrations ranging from 10-1000 ng/mL. The apparent mean (95% CL) volume
of distribution at steady-state was 942 (870, 1014) mL/kg body weight.
Oclacitinib is metabolized in the dog to multiple metabolites and one major oxidative
metabolite was identified in plasma and urine. Overall the major clearance route is metabolism
with minor contributions from renal and biliary elimination. Inhibition of canine cytochrome
P450 enzymes by oclacitinib is minimal; the inhibitory concentrations (IC
50s
) are 50 fold greater
than the observed C
max
values at the use dose.
Mean (95% CL) total body oclacitinib clearance from plasma was low – 316 (237, 396) mL/h/kg
body weight (5.3 mL/min/kg body weight). Following IV and PO administration, the terminal
t
1/2
appeared similar with mean values of 3.5 (2.2, 4.7) and 4.1 (3.1, 5.2) hours, respectively.
Effectiveness:
Control of Atopic Dermatitis
A double-masked, 112-day, controlled study was conducted at 18 U.S. veterinary hospitals.
The study enrolled 299 client-owned dogs with atopic dermatitis. Dogs were randomized to
treatment with APOQUEL (152 dogs: tablets administered at a dose of 0.4-0.6 mg/kg per
dose twice daily for 14 days and then once daily) or placebo (147 dogs: vehicle control,
tablets administered on the same schedule). During the study, dogs could not be treated
with other drugs that could affect the assessment of effectiveness, such as corticosteroids,
anti-histamines, or cyclosporine. Treatment success for pruritus for each dog was defined
as at least a 2 cm decrease from baseline on a 10 cm visual analog scale (VAS) in pruritus,
assessed by the Owner, on Day 28. Treatment success for skin lesions was defined as a 50%
decrease from the baseline Canine Atopic Dermatitis Extent and Severity Index (CADESI)
score, assessed by the Veterinarian, on Day 28. The estimated proportion of dogs with
Treatment Success in Owner-assessed pruritus VAS score and in Veterinarian-assessed
CADESI score was greater and significantly different for the APOQUEL group compared to
the placebo group.
Estimated Proportion of Dogs with Treatment Success, Atopic Dermatitis
Effectiveness
Parameter
APOQUEL
Placebo P-value
Owner-Assessed Pruritus VAS 0.66
(n = 131)
0.04
(n = 133)
p<0.0001
Veterinarian-
Assessed CADESI 0.49
(n = 134)
0.04
(n = 134)
p<0.0001
Compared to the placebo group, mean Owner-assessed pruritus VAS scores (on Days 1, 2,
7, 14, and 28) and Veterinarian-assessed CADESI scores (on Days 14 and 28) were lower
(improved) in dogs in the APOQUEL group. By Day 30, 86% (127/147) of the placebo group
dogs and 15% (23/152) of the APOQUEL group dogs withdrew from the masked study
because of worsening clinical signs, and had the option to enroll in an unmasked study
and receive APOQUEL. For dogs that continued APOQUEL treatment beyond one month,
the mean Owner-assessed pruritus VAS scores and Veterinarian-assessed CADESI scores
continued to improve through study end at Day 112.
Control of Pruritus Associated with Allergic Dermatitis
A double-masked, 30-day, controlled study was conducted at 26 U.S. veterinary hospitals.
The study enrolled 436 client-owned dogs with a history of allergic dermatitis attributed to one
or more of the following conditions: atopic dermatitis, flea allergy, food allergy, contact allergy,
and other/unspecified allergic dermatitis. Dogs were randomized to treatment with APOQUEL
(216 dogs: tablets administered at a dose of 0.4-0.6 mg/kg twice daily) or placebo (220 dogs:
vehicle control, tablets administered twice daily). During the study, dogs could not be treated
with other drugs that could affect the assessment of pruritus or dermal inflammation such as
corticosteroids, anti-histamines, or cyclosporine. Treatment success for each dog was defined
as at least a 2 cm decrease from baseline on a 10 cm visual analog scale (VAS) in pruritus,
assessed by the Owner, on at least 5 of the 7 evaluation days. The estimated proportion of
dogs with Treatment Success was greater and significantly different for the APOQUEL group
compared to the placebo group.
Owner-Assessed Pruritus VAS Treatment Success, Allergic Dermatitis
Effectiveness
Parameter
APOQUEL
(n = 203)
Placebo
(n = 204)
P-value
Estimated Proportion
of Dogs with
Treatment Success
0.67 0.29
p<0.0001
After one week of treatment, 86.4% of APOQUEL group dogs compared with 42.5% of
placebo group dogs had achieved a 2 cm reduction on the 10 cm Owner-assessed pruritus
VAS. On each of the 7 days, mean Owner-assessed pruritus VAS scores were lower in dogs
in the APOQUEL group (See Figure 1). Veterinarians used a 10 cm VAS scale to assess
each dog’s dermatitis. After one week of treatment, the mean Veterinarian-assessed VAS
dermatitis score for the dogs in the APOQUEL group was lower at 2.2 cm (improved from a
baseline value of 6.2 cm) compared with the placebo group mean score of 4.9 cm (from a
baseline value of 6.2 cm). For dogs that continued APOQUEL treatment beyond one week, the
Veterinarian-assessed dermatitis scores continued to improve through study end at Day 30.
Figure 1: Owner Assessed Pruritus VAS Scores by treatment for Days 0-7
Animal Safety:
Margin of Safety in 12 Month Old Dogs
Oclacitinib maleate was administered to healthy, one-year-old Beagle dogs twice daily for
6 weeks, followed by once daily for 20 weeks, at 0.6 mg/kg (1X maximum exposure dose,
8 dogs), 1.8 mg/kg (3X, 8 dogs), and 3.0 mg/kg (5X, 8 dogs) oclacitinib for 26 weeks. Eight
dogs received placebo (empty gelatin capsule) at the same dosage schedule. Clinical
observations that were considered likely to be related to oclacitinib maleate included
papillomas and a dose-dependent increase in the number and frequency of interdigital
furunculosis (cysts) on one or more feet during the study. Additional clinical observations
were primarily related to the interdigital furunculosis and included dermatitis (local alopecia,
erythema, abrasions, scabbing/crusts, and edema of feet) and lymphadenopathy of peripheral
nodes. Microscopic findings considered to be oclacitinib maleate-related included decreased
cellularity (lymphoid) in Gut-Associated Lymphoid Tissue (GALT), spleen, thymus, cervical
and mesenteric lymph node; and decreased cellularity of sternal and femoral bone marrow.
Lymphoid hyperplasia and chronic active inflammation was seen in lymph nodes draining feet
affected with interdigital furunculosis. Five oclacitinib maleate-treated dogs had microscopic
evidence of mild interstitial pneumonia. Clinical pathology findings considered to be oclacitinib
maleate-related included mild, dose-dependent reduction in hemoglobin, hematocrit, and
reticulocyte counts during the twice daily dosing period with decreases in the leukocyte
subsets of lymphocytes, eosinophils, and basophils. Total proteins were decreased over time
primarily due to the albumin fraction.
Vaccine Response Study
An adequate immune response (serology) to killed rabies (RV), modified live canine distemper
virus (CDV), and modified live canine parvovirus (CPV) vaccination was achieved in eight
16-week old vaccine naïve puppies that were administered oclacitinib maleate at 1.8 mg/kg
oclacitinib (3X maximum exposure dose) twice daily for 84 days. For modified live canine
parainfluenza virus (CPI), < 80% (6 of 8) of the dogs achieved adequate serologic response.
Clinical observations that were considered likely to be related to oclacitinib maleate treatment
included enlarged lymph nodes, interdigital furunculosis, cysts, and pododermatitis. One
oclacitinib maleate-treated dog (26-weeks-old) was euthanized on Day 74 after physical
examination revealed the dog to be febrile, lethargic, with pale mucous membranes and
frank blood in stool. Necropsy revealed pneumonia of short duration and evidence of chronic
lymphadenitis of mesenteric lymph nodes. During the three month recovery phase to this
study, one oclacitinib maleate-treated dog (32-weeks old) was euthanized on Day 28 due to
clinical signs which included enlarged prescapular lymph nodes, bilateral epiphora, lethargy,
mild dyspnea, and fever. The dog showed an elevated white blood cell (WBC) count. Necropsy
revealed lesions consistent with sepsis secondary to immunosuppression. Bone marrow
hyperplasia was consistent with response to sepsis.
Margin of Safety in 6 Month Old Dogs
A margin of safety study in 6-month-old dogs was discontinued after four months due to the
development of bacterial pneumonia and generalized demodex mange infections in dogs in
the high dose (3X and 5X) treatment groups, dosed at 1.8 and 3.0 mg/kg oclacitinib twice
daily, for the entire study.
Storage Conditions:
APOQUEL should be stored at controlled room temperature between 20° to 25°C (68° to 77°F)
with excursions between 15° to 40°C (59° to 104°F).
How Supplied:
APOQUEL tablets contain 3.6 mg, 5.4 mg, or 16 mg of oclacitinib as oclacitinib maleate per
tablet. Each strength tablets are packaged in 100 and 250 count bottles. Each tablet is scored
and marked with AQ and either an S, M, or L that correspond to the different tablet strengths
on both sides.
Approved by FDA under NADA # 141-345
Distributed by:
Zoetis Inc.
Kalamazoo, MI 49007
Revised: December 2020
40033180A&P

Specyfikacje produktu

Marka: Zoetis
Kategoria: Niesklasyfikowane
Model: Apoquel

Potrzebujesz pomocy?

Jeśli potrzebujesz pomocy z Zoetis Apoquel, zadaj pytanie poniżej, a inni użytkownicy Ci odpowiedzą


Instrukcje Niesklasyfikowane Zoetis

Zoetis

Zoetis Rimadyl Instrukcja

21 Września 2024
Zoetis

Zoetis Cazitel Instrukcja

17 Września 2024
Zoetis

Zoetis Cerenia Instrukcja

16 Września 2024
Zoetis

Zoetis Apoquel Instrukcja

15 Września 2024

Instrukcje Niesklasyfikowane

Najnowsze instrukcje dla Niesklasyfikowane

Black Diamond

Black Diamond BD1121530000ALL1 Instrukcja

15 Października 2024
Husqvarna

Husqvarna K 970 SmartGuard Instrukcja

15 Października 2024
Stihl

Stihl HT 70 Instrukcja

15 Października 2024
Ernesto

Ernesto H14270 Instrukcja

15 Października 2024
Uniden

Uniden BT MIC KIT Instrukcja

15 Października 2024
Vaude

Vaude Omnis Bike 26 Instrukcja

15 Października 2024
ART

ART ProChannel II Instrukcja

15 Października 2024
Aukey

Aukey DR02J Instrukcja

15 Października 2024
Master Lock

Master Lock 653EURD Instrukcja

15 Października 2024
Roland

Roland FR-18 Diatonic Instrukcja

15 Października 2024